SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options

If you purchased or acquired Skye securities between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

• Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ:SKYE) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”).
• Investors have until January 16, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Allegation Details:

• According to the complaint, throughout the Class Period, Defendants, allegedly made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) nimacimab was less effective than Defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
  
  
• On October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab[.]” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”
  
  
• On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.
  

Next Steps:

• If you purchased or otherwise acquired Skye shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
  

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com